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Abstract
Cryptococcal meningitis is a major cause of mortality throughout the developing world, yet
little is known about the genetic markers underlying Cryptococcal virulence and patient out-
come. We studied a cohort of 230 Cryptococcus neoformans (Cn) isolates from HIV-posi-
tive South African clinical trial patients with detailed clinical follow-up using multi-locus
sequence typing and in vitro phenotypic virulence assays, correlating these data with clini-
cal and fungal markers of disease in the patient. South African Cn displayed high levels of
genetic diversity and locus variability compared to globally distributed types, and we identi-
fied 50 sequence types grouped within the main molecular types VNI, VNII and VNB, with
72% of isolates typed into one of seven 'high frequency' sequence types. Spatial analysis
of patients’ cryptococcal genotype was not shown to be clustered geographically, which
might argue against recent local acquisition and in favour of reactivation of latent infection.
Through comparison of MLST genotyping data with clinical parameters, we found a relation-
ship between genetic lineage and clinical outcome, with patients infected with the VNB line-
age having significantly worse survival (n=8, HR 3.35, CI 1.51-7.20, p=0.003), and this was
maintained even after adjustment for known prognostic indicators and treatment regimen.
Comparison of fungal genotype with in vitro phenotype (phagocytosis, laccase activity and
CSF survival) performed on a subset of 89 isolates revealed evidence of lineage-associated
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virulence phenotype, with the VNII lineage displaying increased laccase activity (p=0.001)
and ex vivo CSF survival (p=0.0001). These findings show that Cryptococcus neoformans
is a phenotypically heterogeneous pathogen, and that lineage plays an important role in
cryptococcal virulence during human infection. Furthermore, a detailed understanding of
the genetic diversity in Southern Africa will support further investigation into how genetic
diversity is structured across African environments, allowing assessment of the risks differ-
ent ecotypes pose to infection.
Author Summary
Cryptococcus neoformans (Cn) is a yeast that commonly causes meningitis in HIV infected
individuals in Africa, where it may account for up to 500,000 deaths every year. In this
highly translational and multidisciplinary study, we used genetic analysis techniques to
show that Cryptococcus found in Southern Africa represents a hotspot of genetic diversity.
We combined this data with the results of microbiological techniques that assess the natu-
ral virulence traits that the yeast uses to survive and infect humans to further show that
genetic diversity is associated with differences in cryptococcal phenotype. Finally, we ana-
lysed detailed clinical data on patients to investigate the clinical effects of infection with
different lineages, and showed that one genetic lineage (VNB) is significantly associated
with worse survival. Whilst much of our prior knowledge regarding the genetic basis of
virulence is derived from studies on laboratory-adapted cryptococcal strains, our findings
from this large and comprehensive MLST genotyping study of clinical isolates—linking
genotype, phenotype, clinical presentation and outcome—provide direct insights into the
contribution of pathogen lineage to virulence in human cryptococcal meningitis.
Introduction
Cryptococcal meningitis (CM), caused by the fungus Cryptococcus neoformans (Cn) is one of
the major causes of AIDS-related mortality, particularly in sub-Saharan Africa, where it was
estimated to account for as many as 500,000 deaths annually prior to wide scale availability of
antiretroviral therapy (ART) [1]. Despite widening access to ART, acute mortality from HIV-
associated CM in Sub-Saharan Africa ranges between 20 and 50% within the optimised setting
of clinical trials [2], reaching as high as 70% in real-world practice [3,4]. A number of clinical
adverse prognostic markers in HIV-associated CM have been identified, including high fungal
burden at CM diagnosis, poor rate of cryptococcal clearance from patient cerebrospinal fluid
(CSF) during antifungal treatment, and altered mental status at presentation [5,6].
Although these clinical parameters are associated with poor outcome, the mechanisms
underpinning this variation have not yet been fully explored. Patient-to-patient differences in
clinical phenotype likely reflect a complex interplay between host factors (level of immunosup-
pression, immune response phenotype [6], underlying immunogenetics [7]) and pathogen vir-
ulence factors, as well as health system factors such as delays to diagnosis and treatment. We
recently demonstrated an association between the in vitro phagocytosis of clinical cryptococcal
isolates by J774 murine macrophage-like cells and poor patient survival in a cohort of 65
patients with HIV-associated CM [8]. These phenotypic differences are likely the result of
genetic variation between isolates. Since Cryptococcus sp. are environmental, and infection is
not horizontally transmitted between patients (infections are opportunistic and the human is a
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dead-end host), it is likely that virulence traits enabling Cn infection to occur are a result of the
organism’s innate ability to survive in the human, perhaps developed as a defence against envi-
ronmental predation [9]. Consequentially, long term natural selection of Cn by human antimi-
crobial defences does not occur, with the attendant likelihood that virulence factors will
demonstrate natural variation within and amongst lineages. Previous studies in other patho-
genic microorganisms and fungi have shown evidence of genetic lineage associated with phe-
notype and clinical outcome [10–12], and a recent study of 140 Cn isolates from Uganda
provided the first evidence of this in Cryptococcus [13].
Of the two cryptococcal species known to infect humans (C. gattii and Cn), the majority of
the global disease burden is caused by the Cn var grubii (Cng) subspecies infecting severely
immunocompromised HIV-infected individuals [14]. Cng can be broadly divided into three
major molecular types: the first two, VNI and VNII, are globally distributed with a third, VNB,
appearing to be endemic to Southern Africa [14,15], although there is growing evidence of
globally distributed VNB [16,17]. There are a number of genotyping schemes available for Cng,
but in 2009 the International Society for Human and Animal Mycology (ISHAM)Working
Group agreed upon a standardised approach using multi locus sequence typing (MLST) of
seven 400–700 bp loci (with a discretionary eighth locus; TEF1) believed to be under neutral
selective pressure [18]. MLST has been extensively used to analyse the evolutionary relatedness
between isolates and studies have shown that disproportionate levels of genetic diversity, both
at the level of the nucleotide and lineage, are present in cryptococcal isolates isolated from
southern Africa when compared to isolates from around the globe [19,20]. Such discrepancies
in the regional diversity of Cn, along with the discovery of sequences that could be considered
‘ancestral’ in southern Africa, have led to the proposal of an ‘out of Africa’ hypothesis, in which
a small number of genotypes from within the broader diversity of African populations have
been spread globally, leading to a clonal expansion of Cn worldwide [19–21].
In this study, we genotyped 230 Cng isolates from well-characterised patients enrolled in
four clinical trials conducted in South Africa using MLST, and studied the genetic diversity of
Cn present in the patients from the region. In a subset of 89 patients, we explored associations
between genotype and in vitro phenotype. Finally, we analysed the whole patient cohort and
looked for relationships between genotype, clinical presentation and outcome of CM. We
hypothesised that genotype was associated with cryptococcal virulence, and that if true, we
would find a correlation between phenotypic and clinical parameters, and the underlying line-
age and genotype of Cn.
Methods
Patients/Isolates
Clinical Cn isolates were obtained as part of four clinical trials conducted in South Africa
(Cape Town and Pietermaritzburg, Kwazulu-Natal) between 2005–2010 [22–25]. Cn was iso-
lated from the CSF of HIV infected individuals prior to the initiation of antifungal treatment
by plating CSF onto Sabouraud Dextrose (SD) agar (Oxoid, Fisher Scientific) and growing at
30°C for 48 hours. A representative sample of the cryptococcal population was stored by taking
a broad ‘sweep’ of all colonies on the plate and stored in cryopreservative medium (80% SD
broth, 20% glycerol) at -80°C until required for further testing.
Molecular Testing
Glycerol stocks of Cn isolates were plated onto SD agar and grown at 30°C for 72 hours. Single
colonies were selected and inoculated in 5 ml SD liquid media, followed by incubation at 37°C
with agitation (165 rpm) for 16 hours. Fungal DNA was extracted using the MasterPure Yeast
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DNA Purification kit (Epicentre) according to the manufacturer’s instructions, but with the
addition of two cycles of rapid bead beating (45 secs, 4.5 m/sec) using a Ribolyser Homogenizer
(Hybaid, Middlesex UK) prior to the heat inactivation step. Genomic DNA was amplified by
PCR using MLST primers for seven loci (CAP59, GPD1, IGS1, LAC1, PLB1, SOD1, URA5)
according to the method of Meyer and colleagues [18]. PCR products were purified using a
standard polyethylene-glycol/NaCl method and sequenced on an ABI3730xl DNA Analyser
(Life Technologies) using Big Dye v1.1 chemistry at MRC Clinical Genomics Centre (Ham-
mersmith, London, UK). Mating type was determined using by PCR according to the method
of Barretto de Oliveira and colleagues [26].
Phenotyping
Genotyping had not been completed when previous phenotyping work was performed [8], and
therefore samples were not evenly selected or distributed across genotypes. For the current
analysis, sufficient samples to represent each major MLST type were randomly selected and
phenotyped to ensure a minimum of 5 samples of each genotype. In vitro phenotyping was per-
formed on a further 32 samples using the CSF survival, laccase activity, and phagocytosis (mac-
rophage uptake) assays as described in detail previously [8]. Briefly, CSF survival was tested
using a standardised Cn inoculum incubated in pooled human CSF at 37°C for 96 hours, with
sampling, plating and CFU counts performed every 12 hours, with the results plotted as a sur-
vival slope. Laccase activity was measured by inoculation and incubation of Cn in L-DOPA
containing culture medium to induce melanin production. Pigment secreted into culture
medium was measured by spectrophotometry, and all results were normalised to that of the
H99 reference strain and expressed as a ratio. Phagocytosis was measured in vitro by infecting
J774 macrophage-like murine cells (obtained from the European Collection of Cell Cultures)
in 24-well culture plates with a multiplicity of infection of 10 Cn cells opsonised with monoclo-
nal anti-capsule (18B7). After 2 hours, macrophages were washed, and internalised Cn cells
released by lysing the macrophages with water and counted using a Haemocytometer. Two to
six replicates were performed for laccase and phagocytosis assays, and all phenotypic data was
analysed using the median of all replicates.
Data Analysis
DNA sequences were assembled using CodonCode Aligner (CodonCode Corporation) and
consensus sequences aligned using BioEdit software [27]. MLST alleles and sequence types were
assigned by comparison with reference alleles using BLAST software [28]. Novel alleles were
submitted to mlst.mycologylab.net for assignment of allele and sequence types. Examples of
each MLST locus were submitted to the European Nucleotide Archive (www.ebi.ac.uk; Acces-
sion numbers LN812026-LN812094). Phylogenetic analyses were performed on concatenated
MLST loci sequences using RAxML (GTR gamma substitution model, sequence partitioned by
loci, 1000 bootstraps performed using rapid hill-climbing methodology; [29]). For the purposes
of molecular analysis, the IGS1 sequence was removed from all concatamers over the aligned
region of indels (nt 1306–1829 in H99) in order to avoid excessive bias due to insertions/dele-
tions (indels). Major molecular types were assigned according to phylogenetic clade in conjunc-
tion with agreed reference type strains available online (H99 andWM148, VNI; WM626, VNII;
Bt1, VNB). BURST analysis was performed using eBURST [30] with branches defined based on
up to two allele changes. SplitsTree4 [31] was used to generate a neighbour network from the
nucleotide sequence alignment. Analysis in STRUCTURE(v2.3.4) was performed using the
admixture model, allowing alpha to be inferred and assuming correlated allele frequencies, with
a Burnin period of 10,000 Markov chain Monte Carlo (MCMC) replications followed by 10,000
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sampling replications [32]. Twenty runs of STRUCTURE analyses were performed for K values
1–20, and data were analysed using the method of Evanno and colleagues as implemented in
StructureHARVESTER [33,34]. The same conditions in STRUCTURE were applied to the link-
age model, and the results were compared with those of the admixture model and found to be
equivalent. A consensus STRUCTURE plot was obtained from the admixture repeats using the
greedy algorithm in CLUMPP [35], and final plots were produced in STRUCTURE PLOT [36].
Address information was available for most patients, but due to the temporary nature of
some township dwellings, as well as ongoing urban redevelopment, this information was
incomplete. Google Maps and the City of Cape Town interactive viewer (www.capetown.gov.
za) were used to determine GPS coordinates based on full address or property identifier
linked to ward. In a very small proportion of cases, a specific location could not be deter-
mined, and the GPS coordinate was mapped to the centre of the nearest matching ward or
district. Spatial data was anonymised and converted to a distance matrix for analysis (S2 File).
The possible presence of spatial autocorrelation between concatenated MLST sequences was
tested using a Mantel correlogram using R package ‘vegan’ (Version 2.2.1) [37] and a genetic
variogram using R package ‘phylin’ (Version 1.0)[38] in R (Version 3.1.2)[39]. See S1 File for
more details.
Statistical analyses of clinical and molecular data were performed using STATA 13.1 (Stata-
Corp. 2007. Stata Statistical Software. College Station, TX: StataCorp LP.). Most phenotypic
and clinical analyses were performed on non-parametric data. Groups were compared using
Kruskal-Wallis test for continuous data and Chi square test for Boolean data. Comparison of
continuous variables to one another (such as phenotypic variables) was performed using linear
regression. Patient survival data was tested using Cox’s proportional hazard analysis, adjusting
for known adverse prognostic indicators. Multivariate linear regression models were con-
structed by initially determining clinical and microbiological factors associated in univariate
analysis (P<0.1), and then added to the model in stepwise fashion as previously described [6].
Ethics Statement
Ethical approval was obtained from the research ethics committees of The Faculty of Health
Sciences, University of Cape Town, The Medicines Control Council of South Africa, The Uni-
versity of Kwazulu-Natal, Edendale Hospital, the Kwazulu-Natal Department of Health, and
by Wandsworth local research ethics committee, covering St George’s Hospital, UK. Informed
written patient consent was obtained for further testing of isolates as part of the clinical trial
protocol.
Accession Numbers
EMBL Accession Numbers for sequences:LN812026, LN812027, LN812028, LN812029,
LN812030, LN812031, LN812032, LN812033, LN812034, LN812035, LN812036, LN812037,
LN812038, LN812039, LN812040, LN812041, LN812042, LN812043, LN812044, LN812045,
LN812046, LN812047, LN812048, LN812049, LN812050, LN812051, LN812052, LN812053,
LN812054, LN812055, LN812056, LN812057, LN812058, LN812059, LN812060, LN812061,
LN812062, LN812063, LN812064, LN812065, LN812066, LN812067, LN812068, LN812069,
LN812070, LN812071, LN812072, LN812073, LN812074, LN812075, LN812076, LN812077,
LN812078, LN812079, LN812080, LN812081, LN812082, LN812083, LN812084, LN812085,
LN812086, LN812087, LN812088, LN812089, LN812090, LN812091, LN812092, LN812093,
LN812094.
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Results
Allele Types, MLST Types, Molecular Types and Diversity/Distribution
Single colonies of Cryptococcus neoformans isolated from CSF of 230 HIV-positive clinical
patients were sequenced for all seven loci according to the ISHAM typing scheme [18], and
MLST genotypes assigned (Fig 1). MLST profiling of Cn revealed great genetic diversity within
South African patients, with 50 different sequence types (STs), including at least 18 novel STs.
One hundred and sixty eight (72%) of isolates were typed as one of seven ‘high frequency’
genotypes containing 9 or more examples (ST4, 4%; ST5, 12%; ST23, 8%; ST32, 7%; ST69, 14%;
Fig 1. Assignment of MLST alleles, phylogeny and distribution of clinical isolates. Unrooted, ordered maximum likelihood tree (RAxML, GTR gamma,
partitioned by loci) using concatenated nucleotide sequences from 7 loci and one representative sequence for each MLST type. Bootstrap values are shown
for branches with greater than 60% agreement between replicates (1000 replicates). Also showing allele typing and MLST assignment for each sequence
type, molecular type assignment according to phylogeny, and number of isolates belonging to each ST type.
doi:10.1371/journal.pntd.0003847.g001
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ST93, 14%; ST40, 13%), with the remaining samples (n = 62) broadly distributed into 43 ‘low
frequency’ genotypes (Fig 1). Mating type was successfully obtained for 229 isolates, of which
226 were found to be typeMATα, with the remaining 3 isolates (each of different ST: ST238,
ST239, ST249; two VNI, one VNB) having theMATa type.
A small number of extremely unusual IGS1 sequences were identified: IGS1 allele types 55,
56, 57 and 58 were all closely related sequences that demonstrated large indels in relation to all
other known IGS1 sequences, and large parts of the IGS1 allele sequence could not be effec-
tively aligned with the other reference alleles. Analysis of the allele types reported at mlst.myco-
logylab.net showed that types 56 and 58 have only been described in ST210, ST221 and ST222,
whilst allele types 55 and 57 (reported here in ST249 and ST263) have also previously been
described in ST225 and ST224. The degree of change affecting a single locus meant that whilst
allelic analyses based on MLST were unaffected, phylogenetic analyses based on nucleotide var-
iation were heavily biased to classify isolates that contained these alleles as outliers. To over-
come this, the affected region of IGS1 was removed from the concatamer of all sequence types
(ST) prior to phylogenetic analysis.
Concatenated nucleotide sequences for all loci were used to generate an unrooted maximum
likelihood tree (Fig 1), allowing broad phylogenetic clades (molecular types) to be determined
that included all MLST STs. Cn Isolates were then categorised by molecular type, with the larg-
est proportion being VNI (n = 175, 76%), followed by VNII (n = 47, 20%) and VNB (n = 8,
4%) (Fig 1). Of the 50 sequence types identified, 30 were found to be VNI, with most VNI sam-
ples (n = 128, 73%) grouping into one of the high frequency sequence types (ST5, ST23, ST32,
ST69 and ST93) described earlier. The VNII molecular type contained 14 sequence types, the
majority of which (n = 31, 66%) were of the high frequency ST40. The relatively low frequency
VNB molecular type did not contain any high frequency sequence types, with eight isolates
divided amongst six sequence types.
Since our dataset contained isolates belonging to 50 different MLST types, many of which
contained only one or two isolates (thus limiting statistical power for detecting associations), it
was necessary to determine a rationale for grouping samples. We chose to analyse isolates
grouped by molecular type and by the high frequency MLST types (Fig 1). Previous authors
have used BURST grouping to cluster isolates [13,21,40], and although we considered applying
the same methodology, eBURST grouping [30] of our dataset identified at least 10 distinct and
unrelated clusters, most dominated by a single high frequency MLST type along with a very
small number of ancillary types, and such groupings did not add power to the analyses over
using individual sequence types (Fig A in S1 File). We instead used SplitsTree [31] to define
molecular types, and found the VNI clade to be highly clonal (Fig 2A). To further study the
population distribution of the VNI clade, we analysed the nucleotide sequences with an admix-
ture model in STRUCTURE [32], and evaluated the optimal number of clusters using Struc-
tureHARVESTER [33,34]. This showed the optimal number of clusters (k) within VNI to be
three (Fig 2B), and demonstrated distinct subpopulations in our VNI dataset, here defined as
VNI(a), VNI(b) and VNI(c) (Fig 2C).
Spatial Analysis of Clinical Cn Isolates
Out of 230 South African clinical isolates, 185 were from patients resident in Cape Town in the
Western Cape Province. From those patients, 46 different sequence types were found within
the population of a single city. The remaining 45 isolates were from patients in the KwaZulu-
Natal province, where 13 sequence types were found, the most common of which was ST93
(n = 22, 49%), with four sequence types not present in patients from Cape Town (ST236,
Genotype, Phenotype and Clinical Outcome in Cryptococcal Meningitis
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ST238, ST241, ST242). The VNB molecular type was only found in clinical isolates from Cape
Town, and was not found in Kwazulu-Natal.
Cryptococcus is thought to be acquired from the environment, and it is likely that human
exposure is nearly universal [41]. However, it remains unclear whether clinical CM is caused
by recent infection or reactivation and dissemination of previously latent Cn. To explore the
possibility of geographical clustering, indicating a possible source of local acquisition, patient
addresses in Cape Town were mapped using GPS coordinates, and the concatenated MLST
sequences were tested for spatial autocorrelation using a Mantel correlogram [42] and a genetic
variogram (Fig B in S1 File)[43]. No significant spatial autocorrelation could be found at α =
0.05 and semivariogram modelling produced variogram models with a very short range and
poor fit to the data (Fig C in S1 File), indicating an absence of spatial correlation between
genetic and geographic distance in this study.
Fig 2. Phylogenetic and Bayesian analysis of concatenated nucleotide sequences. (A) SplitsTree neighbour network shows diverse VNII and VNB, and
clonal VNI clades. (B) Analysis of VNI clustering using StructureHARVESTER and ΔK shows optimal number of K clusters is 3. (C) Use of STRUCTURE
allows VNI sequences to be subdivided into 3 distinct populations: VNI(a), VNI(b), VNI(c).
doi:10.1371/journal.pntd.0003847.g002
Genotype, Phenotype and Clinical Outcome in Cryptococcal Meningitis
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Phenotypic Associations
In previous studies we explored a number of fungal virulence factors that can be characterised
in the laboratory. These include the activity of the fungal enzyme laccase that catalyses the for-
mation of melanin, the ability of Cryptococcus to survive in the hostile and resource-limited
environment of ex vivo human CSF, and the tendency to be phagocytosed by macrophages. We
reported how isolates that are highly phagocytosed by macrophage-like cells in vitro are
counter-intuitively associated with poor patient survival and increased baseline fungal burden
in vivo [8], and how in vitro phagocytosis is further associated with enhanced in vitro laccase
activity and enhanced survival in ex vivo CSF. We hypothesised that isolates displaying pheno-
typic traits of being highly phagocytosed, with good CSF survival and high laccase activity in
vitro, represent a high virulence phenotype associated with worse outcome in human CM.
Fifty-seven Cn isolates from this previous study were included in our genotyped South African
cohort. However, samples were not sufficiently distributed amongst genotypes to allow us to
probe the relationships between genotype and in vitro phenotype. Therefore, a further 32 iso-
lates were selected from within the cohort based solely on MLST type, and phenotyped using
laccase activity, CSF survival and phagocytosis assays described previously [8]. The resulting
set of 89 phenotyped isolates included a minimum of 5 isolates in each molecular type and
high frequency MLST type, along with a small number of samples from low frequency MLST
types (Table 1).
We then compared the phenotypic data with genotype to test for lineage-associated pheno-
types. When analysed by molecular type, in vitro survival in ex vivo human CSF differed
significantly (Fig 3A, p = 0.0001), with the VNII group having a more shallow survival slope,
indicating significantly better CSF survival (median CSF survival slope -0.38 log10 CFU/ml
/day) compared to VNI (-1.33) and VNB (-1.11). Laccase production also differed significantly
between groups (Fig 3, p = 0.001), with results normalised to the lab-adapted reference strain
H99 indicating that VNII isolates had higher laccase activity (0.66 ratio to H99) compared to
Table 1. In vitro phenotyping results ordered by molecular type, VNI subtype, and high frequency MLST type.
Molecular type VNI Subtype MLST type (high frequency) N° Isolates Laccase Activity
(normalised to
H99N)
CSF Survival (Slope
CFU/ml /day)
Macrophage
Uptake (cells/μl)
median range median range median range
VNI 67 0.34 (0.02–1.12) -1.33 (-3.07–-0.28) 313 (80–1278)
VNI(a) 13 0.27 (0.02–1.12) -0.79 (-1.95–-0.28) 270 (85–538)
ST69 11 0.25 (0.02–1.12) -0.79 (-1.77–-0.28) 250 (85–538)
VNI(b) 12 0.14 (0.03–0.83) -1.8 (-2.34–-0.88) 517 (165–771)
ST23 5 0.12 (0.03–0.44) -1.85 (-2.34–-1.14) 530 (165–705)
VNI(c) 42 0.35 (0.05–0.91) -1.28 (-3.07–-0.41) 312 (80–1278)
ST4 9 0.52 (0.11–0.88) -0.86 (-2.23–-0.52 465 (86–1278)
ST5 10 0.41 (0.06–0.91) -1.05 (-2.22–-0.53) 383 (92–614)
ST32 10 0.41 (0.13–0.54) -1.38 (-2.82–-0.91) 199 (112–605)
ST93 10 0.27 (0.05–0.63) -1.92 (-3.07–-0.96) 297 (80–515)
VNII 14 0.66 (0.32–1.06) -0.38 (-1.01–-0.06) 285 (88–420)
ST40 10 0.71 (0.32–1.06) -0.22 (-0.91–-0.06) 266 (135–350)
VNB 8 (7)* 0.16 (0.03–0.91) -1.44 (-2.32–-0.96) 250 (160–400)
All 89 (88)* 0.36 (0.02–1.12) -1.11 (-3.07–-0.06) 300 (80–1278)
* CSF survival was not performed for one of the eight VNB isolates.
doi:10.1371/journal.pntd.0003847.t001
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VNI (0.34) and VNB (0.16). These two phenotypes were correlated in our previous study [8],
and remained so in this expanded dataset (p = 0.0001). There were no significant differences in
in vitro phagocytosis by macrophages by molecular type.
Analysis within VNI molecular type by subtypes VNI(a), VNI(b) and VNI(c), indicated sig-
nificant differences in CSF survival (Fig 3A, p = 0.01) but not laccase activity or in vitro phago-
cytosis. Analysis by high frequency MLST type also indicated phenotypic variability that was
significant for CSF survival (Fig 3A, p = 0.0001) and laccase activity (Fig 3B, p = 0.002), and
even when the outlying VNII ST40 group was removed, differences in CSF survival between
VNI STs were still present (p = 0.03). Although the VNII molecular type and the VNII ST40
appeared to exhibit both high laccase activity and good CSF survival, no particular MLST type
consistently exhibited a ‘high virulence’ triad of being highly phagocytosed, with high laccase
activity and good CSF survival.
Clinical Associations
We next sought to determine whether clinical parameters and outcome in human CM were
associated with genetic lineage. Of the 230 patients who had their clinical Cn isolates genotyped
in this study, 226 patients received amphotericin B-based induction antifungal therapy, with
Fig 3. Median in vitro phenotyping values ordered by molecular type, VNI Subtype and high frequency MLST. Kruskal Wallis analysis performed on
groups, and p values shown. Overall median is plotted in red. (A) Survival in ex vivo CSF, (B) Laccase Activity normalised to H99 reference strain, (C) In vitro
phagocytosis of isolates by J774 cells (per 1 μl lysate).
doi:10.1371/journal.pntd.0003847.g003
Genotype, Phenotype and Clinical Outcome in Cryptococcal Meningitis
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003847 June 25, 2015 10 / 18
just four patients receiving fluconazole without amphotericin B. Since fluconazole treatment
alone is known to be associated with higher mortality [6], we removed these four patients from
the survival analyses. Where available, details of baseline patient characteristics, CSF findings
and mortality are shown in supplementary information across the whole cohort and split by
major molecular groupings (S1 Table), and by isolate (S3 File).
Long-term survival outcome data was available for all patients, with an overall mortality of
27% at 10 weeks, and 41% at one year. We explored the relationship between patient outcome
and cryptococcal genotype. When samples were analysed by molecular type, survival was simi-
lar in patients infected with isolates belonging to the predominant VNI and VNII molecular
type (Fig 4A), whilst the 8 patients infected with Cn isolates of the VNB molecular type had sig-
nificantly higher mortality at 10 weeks (HR 3.20, CI 1.26–8.09, p = 0.014) and at one year (HR
3.35, CI 1.51–7.20, p = 0.003). This difference was maintained even following adjustment for
previously published adverse prognostic factors [6] of age, weight, baseline haemoglobin, CD4
count, baseline fungal burden and altered mental status, as well as differences in treatment regi-
men (duration of amphotericin B induction therapy, treatment with fluconazole, flucytosine,
Fig 4. Clinical characteristics and survival of patients infected with different lineages of C neoformans. (A) Patient survival by molecular type; VNB
isolates (n = 8) were associated with significantly worse outcome compared to VNI and VNII isolates at 70 days (p = 0.01) and 365 days (p = 0.003) follow-up
in Cox’s proportional hazard survival analysis. (B) Patient survival by high frequency MLST type. (C) Number of patients with and without altered mental
status by molecular group (% with altered mental status indicated above each bar). (D) Baseline fungal burden, showing variation by high frequency MLST
type.
doi:10.1371/journal.pntd.0003847.g004
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or voriconazole as a second drug, adjunctive IFN-γ) in a multivariate analysis (10 week aHR
4.02, CI 1.28–12.67, p = 0.018; 1 year aHR 3.92, CI 1.53–1.006, p = 0.005). Single variable and
multivariate analysis within VNI molecular type showed no significant survival differences
between the VNI(a), VNI(b) and VNI(c) subtypes.
Given that the VNB molecular type is a rare cause of CM globally, we then explored survival
in patients infected with the high frequency South African MLST types found within the glob-
ally distributed VNI and VNII molecular types. There was limited evidence for survival differ-
ences between patients infected with different cryptococcal MLST types (Fig 4B), with patients
infected with ST32 showing worse survival (p = 0.077) after one year in bivariate but not multi-
variate analysis.
To examine these differences in survival by molecular or sequence type, we compared clini-
cal parameters known to be important determinants of outcome in human CM across geno-
types. Patients infected with VNB type were more likely to have altered mental status (Fig 4C;
p = 0.04). There were no significant differences in baseline fungal burden, rate of clearance of
infection or CSF white cell count between patients infected with different molecular types or
VNI subtypes.
Clinical parameters varied by high frequency MLST type (Fig 4C and 4D). The apparent
association between infection with ST32 and poor survival could not be explained by adverse
patient clinical parameters, and ST32 isolates had amongst the lowest baseline fungal burdens
of all groups (Fig 4D). Nor did phenotyping of ST32 reveal attributes of high phagocytosis,
high laccase activity or good CSF survival. Conversely, ST40 isolates within VNII, which based
on in vitro phenotyping might have been expected to be more virulent, showed little difference
in clinical parameters or long-term survival (Fig 4B, 4C and 4D).
In other high frequency sequence types, variations were apparent in baseline fungal burden,
and rate of clearance was significantly different between ST types (p = 0.0001; S1 Table). On
bivariate regression, ST5 was associated with faster rate of clearance from CSF (p = 0.04); how-
ever this association was not maintained following adjustment for other factors associated with
rate of clearance (baseline fungal burden, treatment with amphotericin B, addition of flucyto-
sine, fluconazole or IFN-γ) on multivariate analysis.
Discussion
MLST characterisation of a large number of Cryptococcus neoformans isolates causing menin-
gitis in HIV-infected South African patients revealed high genetic diversity in this region, with
fifty discrete STs in 230 patients. We found 46 different sequence types within patients living in
Cape Town alone. This level of diversity was surprising, as another recent study genotyping
170 South African Cn isolates found just 23 different sequence types, although this study did
not use the ISHAM typing scheme [15]. These South African studies represent a marked con-
trast with most other MLST studies, which have typically reported a relatively low number of
sequence types present in each geographical location [13,21,40,44]. For example, a large recent
study of over 476 clinical and environmental isolates obtained from multiple sites in 8 coun-
tries across Asia and the Middle East found just 28 sequence types, with most countries domi-
nated by 1–3 high frequency genetic lineages [40]. Furthermore, the diversity we observed was
not confined to changes in a single locus, but represented changes in multiple loci, such that
BURST grouping was not a feasible approach for analysis. Despite this diversity, 73% of the iso-
lates (n = 168) were genotyped as one of seven ‘high frequency’ sequence types, with the
remaining 26% of isolates (n = 62) genotyped into 43 different sequence types with between
one and four examples of each type.
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To understand the possible sources of such broad diversity, we mapped patient address data
using GPS coordinates. This revealed that there was no clustering of MLST or molecular types
within Cape Town—within our dataset, the high frequency MLST STs and the different molec-
ular types were spread across patients from all the major townships of Cape Town investigated,
and there was no correlation between spatial and genetic distance. This could perhaps argue
against local acquisition. However, it is difficult to speculate why Cape Town might have such
high sequence diversity within such a small location without performing environmental sam-
pling to establish whether the same MLST types are present in the local environment. One
possible explanation for the observed diversity is that the populations of the Cape Town are
historically transient and migratory, with a very high proportion of residents migrating to
Cape Town from rural areas in the Eastern Cape during the early post-apartheid era [45];
unfortunately information regarding place of birth was not available for individual patients.
Patients with HIV-associated cryptococcosis might be experiencing reactivation of latent cryp-
tococcal infection acquired months or years ago in their village of birth, although some people
of Xhosa ancestry residing in Cape Town do return for regular annual visits to rural locations
in the Eastern Cape, where re-exposure may occur. We did not have information regarding
duration of residence at an address to make any firm conclusions. Molecular epidemiological
studies have previously shown that patients emigrating from Africa to Europe may experience
cryptococcal infection due to strains of African origin many years later [46,47], and therefore
latency is a plausible explanation. Although clearly residents may circulate within and between
townships, even with travel to the Eastern Cape it is unlikely that African patients are more
mobile than Asian patients [40], indicating that the environmental diversity of southern Afri-
can Cn is demonstrably higher than that found elsewhere in the world.
Phylogenetic analysis showed that although most isolates were of the globally distributed
VNI molecular type, there were also a substantial number of VNII isolates, as well as the much
less common VNB molecular type, which in the literature appears to be most commonly
found in southern Africa. Other authors have used BURST analysis for clustering MLST data
[13,21,30,40]. Whilst this is a reasonable approach, it is most effective when analysing a net-
work of closely related sequences connected by changes to a single allele. Furthermore, BURST
analysis is limited by the simplistic allelic definitions of MLST as well as not necessarily captur-
ing the effects of recombination, and thus provides less resolution of sequence relatedness than
that of a phylogeny based on concatenated nucleotide sequences. Cn, in particular VNB, is
known to be highly recombinogenic [14,20,21] so instead of BURST grouping, we used
STRUCTURE [32] to delineate three genetic lineages within VNI isolates and used these
groupings as part of our analyses of phenotypic and clinical association with genotype.
We have previously used in vitro phenotyping to demonstrate the highly variable virulence
of clinical Cryptococcus neoformans isolates. In this study we were able to compare in vitro phe-
notyping data with MLST genotyping data, and showed that these differences are associated
with genetic lineage. In particular, VNII isolates, which are genetically distinct from VNI and
VNB, are also phenotypically distinct, with significantly different laccase activity and survival
in ex vivo human CSF. Within the globally distributed VNI molecular type, a population genet-
ics approach to broadly subdivide isolates into clusters using STRUCTURE increased the sam-
ple size, and showed that one cluster (VNI(a)) had significantly better ex vivo CSF survival
compared to VNI(b) and (c) subtypes. Differences were also detected at the level of the MLST
ST, and whilst ST40 (as the representative VNII ST) might be expected to show differences,
even when ST40 was removed from the analysis we still found differences in CSF survival.
The South African cohort of Cn isolates, from extensively clinically characterised clinical
trial patients with long-term follow-up, provided an excellent resource for study. In this study,
as well as investigating phenotypic variation, we explored the influence of genetic lineage on
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clinical factors. Given that 98% of patients received amphotericin-based induction CM therapy,
differences in treatment regimen were not considered a major contributor to the clinical and
survival variations observed, and indeed we removed those patients not receiving amphotericin
B from the survival analyses. Furthermore, apart from rate of clearance and patient survival, all
clinical parameters studied were from baseline, prior to commencement of anti-fungal treat-
ment, and were therefore considered to be independent of drug regimen.
We initially analysed isolates according to molecular type, and found that the apparently
rare VNB molecular type was associated with poor patient survival, even at the clinically rele-
vant time-point of 10 weeks. The presence of only eight VNB isolates within the dataset means
that this result must be viewed with some scepticism, even though the association of VNB with
patient survival was maintained following adjustment for treatment regimen and baseline
variables likely to be impacting on survival, including altered mental status, an important inde-
pendent adverse prognostic marker [5,6] that was over-represented in this group. The patho-
physiology of altered mental status remains poorly understood [6] and it is uncertain to what
extent it is driven by pathogen or host factors. It is therefore plausible that altered mental status
is on the causal pathway between VNB and mortality. Nevertheless, the differences in long-
term outcome remained significant even after adjustment for all known CM adverse prognostic
markers and treatment regimen. We sought to explain this survival difference within other
clinical parameters, as well by studying the in vitro phenotype for a number of known virulence
factors, but were unable to find a plausible explanation, since VNB isolates were clinically and
phenotypically very similar to VNI isolates. We were thus unable to explain the underlying link
between infection with VNB strains and worse outcome. The factors that underpin the appar-
ent high virulence of VNB need to be further investigated and the findings replicated in a larger
cohort. To date, the VNB molecular type has been most commonly described in Southern
Africa, and may be a rare and unusual genotype; this lineage may be significantly different
from the globally distributed VNI and VNII genotypes (which showed comparable survival
curves).
Since observations relating to VNB may not be broadly applicable to global cryptococcosis,
we analysed the dataset using the seven high frequency MLST types, each of which contained
between 9 and 33 isolates. Although Fig 4B shows clear differences in patient survival between
MLST types, with survival in ST32-infected patients particularly poor, these differences were
not statistically significant. However, this may simply reflect the small sample size for each ST.
The broad genetic diversity of Cn isolates infecting patients precluded the comparison of
large groups of highly related sequences, limiting the statistical power to detect genotype-phe-
notype associations. Clustering VNI isolates using STRUCTURE, although useful from a
population genetics standpoint, did not demonstrate strong clinical or survival differences.
Another important caveat of this work is that we sequenced single colonies from each
patient’s Cn isolate. Mixed infections have been reported in up to 20% of patients with CM
[48], and by sequencing only a single colony we may have missed the lineage responsible for
clinical and phenotypic results.
When both clinical and phenotypic characteristics are compared according to genetic line-
age, it becomes clear that rather than being a homogenous group, different lineages of Crypto-
coccus exhibit a wide range of differences both within and between lineages, and that many of
these differences may be the result of inherited traits. This raises important questions about the
use of historically cultured and passaged reference strains such as H99 for inferring the signifi-
cance of genes and in ‘knock-down’ studies, as well as the use of small numbers of representa-
tive ‘type’ strains to describe genotypes. We would advocate larger samples sizes with increased
sample diversity, as well as ensuring comparative analyses are performed on samples of similar
genetic background.
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As our study shows, significant clinical and phenotypic differences are detectable between
genetic lineages. However unravelling the complex relationships between pathogen genetic
diversity and disease presentation and outcome in an immunocompromised host is difficult.
Although this study represents a large number of clinical trial patients, the diversity within the
dataset meant that genotypic groups were small, reducing the power of the analyses. Further-
more, other variables, such as host immunogenetics and immune response, delays to clinical
presentation, variable access and adherence to antifungal and antiretroviral treatment, and the
possibility of further opportunistic infections are all elements that impact on long-term sur-
vival and cannot be controlled for in a human population, particularly in the context of a
developing world health-care system. Further work in an animal model would allow more con-
trolled exploration of the influence of genetic diversity on clinical outcome, albeit with the
caveats that such non-human models represent. Finally, MLST captures only a small fraction
of the sequence diversity and poorly accounts for recombination. Whole genome sequencing is
becoming increasingly affordable [49], and is currently underway for isolates from well-charac-
terised patient cohorts. In sufficient numbers this will allow genome wide association studies to
be performed, allowing identification of the alleles associated with pathogenesis and virulence,
with the eventual aim of identifying novel drug targets.
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